Skip to main content
. 2022 Feb 23;13(6):1829–1842. doi: 10.1016/j.jcmgh.2022.02.011

Figure 5.

Figure 5

Acute GLP-2R antagonism decreases the proportion of jejunal Lgr5+ ISCs in S-phase. (A) Acute GLP-23–33 treatment protocol; the green mouse indicates use of Lgr5-eGFP-IRES-creERT2 animals (created using Biorender.com). (B) Percentage of total eGFP+ ISCs that incorporated EdU. (C) Total number of eGFP+ ISCs per crypt. (D) Percentage of total OLFM4+ ISCs that incorporated EdU. (E) Total number of OLFM4+ ISCs per crypt. (B–E) N = 3–5. ∗P < .05.